[go: up one dir, main page]

JO3601B1 - مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 - Google Patents

مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2

Info

Publication number
JO3601B1
JO3601B1 JOP/2015/0178A JOP20150178A JO3601B1 JO 3601 B1 JO3601 B1 JO 3601B1 JO P20150178 A JOP20150178 A JO P20150178A JO 3601 B1 JO3601 B1 JO 3601B1
Authority
JO
Jordan
Prior art keywords
compounds
dihydropyrazolo
pyrazin
allosteric modulators
negative allosteric
Prior art date
Application number
JOP/2015/0178A
Other languages
English (en)
Inventor
José Ignacio Andrés-Gil
Gool Michiel Luc Maria Van
O'scar Delgado-Gonza'lez
Diego Sergio-Alvar Alonso-De
Lucas Olivares Ana Isabel De
Andrés Avelino Trabanco-Sua'rez
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of JO3601B1 publication Critical patent/JO3601B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

يتعلق الاختراع الحالي بمشتقات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون بصفتها منظمات الوسترية سلبية لمستقبل جلوتاميت ميتاتروبي نوع فرعي 2. كما يتعلق الاختراع بتركيبات صيدلانية تشتمل على هذه المركبات وبعمليات تحضير هذه المركبات والتركيبات واستخدام هذه المركبات والتركيبات لمنع أو معالجة الاضطرابات التي تتضمن مستقبل جلوتاميت ميتاتروبي نوع فرعي 2 .
JOP/2015/0178A 2014-08-01 2015-07-27 مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 JO3601B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14179599 2014-08-01

Publications (1)

Publication Number Publication Date
JO3601B1 true JO3601B1 (ar) 2020-07-05

Family

ID=51257438

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2015/0178A JO3601B1 (ar) 2014-08-01 2015-07-27 مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2

Country Status (15)

Country Link
US (1) US10112949B2 (ar)
EP (1) EP3174880B1 (ar)
JP (1) JP6615864B2 (ar)
KR (1) KR102531693B1 (ar)
CN (1) CN106573935B (ar)
AR (1) AR101393A1 (ar)
AU (1) AU2015295299B2 (ar)
BR (1) BR112017001998A2 (ar)
CA (1) CA2954218C (ar)
EA (1) EA031038B1 (ar)
ES (1) ES2702192T3 (ar)
JO (1) JO3601B1 (ar)
MX (1) MX2017001453A (ar)
TW (1) TWI696625B (ar)
WO (1) WO2016016381A1 (ar)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20150177B1 (ar) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
JOP20150179B1 (ar) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
ES2727379T3 (es) * 2014-12-03 2019-10-15 Janssen Pharmaceutica Nv Compuestos de 6,7-dihidropirazolo[1,5-a]pirazin-4(5H)-ona y su uso como moduladores alostéricos negativos de receptores de mGlu2
US10967078B2 (en) 2014-12-03 2021-04-06 Janssen Pharmaceutica Nv Radiolabelled mGluR2 PET ligands
SI3389727T1 (sl) 2015-12-18 2020-10-30 Janssen Pharmaceutica Nv Radioaktivno označeni ligandi PET MGLUR2/3
EP3389728B1 (en) 2015-12-18 2020-08-05 Janssen Pharmaceutica NV Radiolabelled mglur2/3 pet ligands
EP3719023B1 (en) 2017-11-24 2024-10-16 Sumitomo Pharma Co., Ltd. 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINONE DERIVATIVE AND MEDICAL USE THEREOF

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004054665A1 (de) * 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte bi- und tricyclische Pyrazol-Derivate Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
AU2006226669B2 (en) * 2005-03-23 2011-12-08 F. Hoffmann-La Roche Ag Acetylenyl-pyrazolo-pvrimidine derivatives as mGluR2 antagonists
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
US8592422B2 (en) * 2010-12-17 2013-11-26 Vanderbilt University Bicyclic triazole and pyrazole lactams as allosteric modulators of mGluR5 receptors
WO2012172093A1 (en) * 2011-06-17 2012-12-20 Merz Pharma Gmbh & Co. Kgaa Dihydroindolizine derivate as metabotropic glutamate receptor modulators
MX344308B (es) 2011-11-03 2016-12-13 Merck Sharp & Dohme Derivados de quinolina carboxamida y quinolina carbonitrilo como moduladores alostericos negativos de mglur2, composiciones y su uso.
EP2666775A1 (en) 2012-05-21 2013-11-27 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
WO2013192350A1 (en) * 2012-06-20 2013-12-27 Vanderbilt University Substituted bicyclic aralkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors
WO2013192347A1 (en) * 2012-06-20 2013-12-27 Vanderbilt University Substituted bicyclic cycloalkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors
CA2876979A1 (en) * 2012-06-20 2013-12-27 P. Jeffrey Conn Substituted bicyclic alkoxy pyrazole analogs as allosteric modulators of mglur5 receptors
AR093077A1 (es) * 2012-10-23 2015-05-20 Hoffmann La Roche ANTAGONISTAS DE mGlu2/3 PARA EL TRATAMIENTO DE LOS TRASTORNOS AUTISTAS
RU2708391C2 (ru) * 2014-08-01 2019-12-06 Янссен Фармацевтика Нв 6,7-дигидропиразоло[1,5-а]пиразин-4(5h)-оновые соединения и их применение в качестве отрицательных аллостерических модуляторов рецепторов mglur2

Also Published As

Publication number Publication date
JP2017523201A (ja) 2017-08-17
JP6615864B2 (ja) 2019-12-04
EP3174880B1 (en) 2018-09-26
AU2015295299A1 (en) 2017-01-19
KR102531693B1 (ko) 2023-05-10
MX2017001453A (es) 2017-05-11
US10112949B2 (en) 2018-10-30
CN106573935A (zh) 2017-04-19
EA031038B1 (ru) 2018-11-30
CA2954218A1 (en) 2016-02-04
BR112017001998A2 (pt) 2017-12-12
AU2015295299B2 (en) 2019-05-02
TWI696625B (zh) 2020-06-21
KR20170032464A (ko) 2017-03-22
CA2954218C (en) 2022-11-29
CN106573935B (zh) 2020-01-17
EA201692496A1 (ru) 2017-06-30
AR101393A1 (es) 2016-12-14
WO2016016381A1 (en) 2016-02-04
EP3174880A1 (en) 2017-06-07
US20180222908A1 (en) 2018-08-09
ES2702192T3 (es) 2019-02-27
TW201609742A (zh) 2016-03-16

Similar Documents

Publication Publication Date Title
PH12017500161A1 (en) 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
PH12015502685A1 (en) 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
PH12017500170A1 (en) 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors
JO3601B1 (ar) مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
SG10201804868PA (en) Compounds for the inhibition of indoleamine-2,3-dioxygenase
MY193728A (en) Muscarinic receptor agonists
MX389592B (es) Moduladores alostericos positivos del receptor m1 muscarinico
EA033281B1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
NZ736055A (en) Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
PH12016500312A1 (en) 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
MY192609A (en) Substituted bicyclic heteroaryl compounds as rxr agonists
NZ740587A (en) Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
IN2013MU03838A (ar)